A Phase 3 interventional study of busulfan, cyclophosphamide and melphalan, BuCyMel and clofarabine, fludarabine and busulfan, CloFluBu in Acute Myeloid Leukemia (AML) in Remission and Stem Cell Transplantation, sponsored by Vastra Gotaland Region. Recruiting at 17 sites in 10 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-12-19.
Sponsored by Vastra Gotaland Region · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Leukemia, Myeloid, Acute with a site in Belgium — 15 open to participants now, 29 under way, 14 of them phase 3. Leukemia, Myeloid, Acute · Belgium.
Among the 108 studies in Leukemia, Myeloid, Acute with a site in Belgium, this one is the 54th largest by planned enrollment of the 104 interventional ones that give a count, is one of 6 that started in 2022, is one of 48 in phase 3, reaches primary completion later than 23 of the 28 other live ones, and was the 98th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →15 of the 108 studies in Leukemia, Myeloid, Acute with a site in Belgium are open now. Recruiting first, the newest first:
Stichting Hemato-Oncologie voor Volwassenen Nederland · Sites in Belgium, United States, Australia and 10 more countries
Ages 18+
Syndax Pharmaceuticals · Sites in Belgium, United States, Argentina and 20 more countries
Ages 12+
Kura Oncology, Inc. · Sites in Belgium, United States, Australia and 14 more countries
Ages 18+
Stichting Hemato-Oncologie voor Volwassenen Nederland · Sites in Belgium, Austria, Denmark and 13 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Belgium, United States, Australia and 23 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 37 · Phase 3 50 · Phase 4 2
First in 1993; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 176 across the 104 interventional studies, 304 across the 3 observational. Of the 66 that completed or were terminated, 40 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 108 have an industry lead sponsor. The 10 most frequent:
Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
Vastra Gotaland Region has 4 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
6 of the studies in Leukemia, Myeloid, Acute with a site in Belgium that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03839771Phase 3Stichting Hemato-Oncologie voor Volwassenen NederlandA Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | 2027-04-17 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT03793478Daiichi SankyoSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | 2027-05-01 |
| NCT04988555Sumitomo Pharma America, Inc.A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 108 studies in Leukemia, Myeloid, Acute with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival than a conditioning regimen combining three alkylating agents (BuCyMel)
The study is designed as an open-label randomized phase III, multicenter superiority trial comparing two conditioning regimens CloFluBu and BuCyMel in children with acute myeloid leukemia (AML) with per-protocol indications to allogeneic hematopoietic stem cell transplantation with a myeloablative conditioning.
This study is composed of two parts - an interventional part that includes randomization, and an observational part. The interventional part is a phase III randomized, open label, multicenter parallel group trial comparing two conditioning regimens used in pediatric HCT: a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm) and a combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm). The observational part will prospectively register outcome measures of transplantation in patients not fulfilling criteria for participation in the interventional part of the study (due to lack of complete remission, lack of matched sibling or unrelated donor, who were not recruited to a national upfront protocol or who decline participation in randomization) but consenting to registration of the data.
Inclusion criteria for randomization part of the study:
\< 5 % leukemic blasts confirmed by flow cytometry (in patients with an informative leukemia associated immunophenotype) in a bone marrow sample taken ≤14 days prior to start of conditioning and no evidence of extramedullary disease, including in CNS and no leukemic blasts in the peripheral blood (verified by flow cytometry in case immature cells are detected in the peripheral blood differential).
-Patients must have a related or unrelated donor fulfilling any of the following criteria: HLA 10/10 allelic matched, identical, sibling BM donor or HLA 10/10 or 9/10 allelic matched related/unrelated BM or PBSC donor orHLA 5-6/6 unrelated or 6-7-8/8 unrelated Cord Blood (UCB)
Inclusion criteria for observation/registration only:
Exclusion criteria for the randomization part of the study :
Exclusion criteria for the observational part of the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
a combination of busulfan, cyclophosphamide and melphalan, conditioning regimen
Drug: busulfan, cyclophosphamide and melphalan, BuCyMel
a combination of clofarabine, fludarabine and busulfan conditioning regimen
Drug: clofarabine, fludarabine and busulfan, CloFluBu
a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)
Also known as: BuCyMel
combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm)
Also known as: CloFluBu
2-year, acute grade III to IV-free, chronic non-limited GvH-free, relapse-free survival (GREF)
To investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival (GRFS) than a conditioning regimen combining three alkylating agents (BuCyMel)
Time frame: 2 years
Neutrophil and platelet engraftment
time to engraftment after stem cells transplantation, in all patients
Time frame: 28 days post transplantation
Primary graft failure
The incidence of graft failure defined as neutrophil recovery by day +28 post transplantation
Time frame: +28 days post transplantation
Secondary graft failure
The incidence of secondary graft failure
Time frame: 2 years
Cumulative incidence of relapse
The incidence of cumulative incidence of relapse during the first two years after transplantation
Time frame: 2 years
The association between pre-HCT MRD and relapse
% of remaining leukemic cells in the last bone marrow sample taken before start of conditioning
Time frame: 2 years
Cumulative incidence of transplant-related mortality
The incidence of transplant-related mortality at 2 years
Time frame: 2 years
Disease-free survival
Disease-free survival at 2 years
Time frame: 2 years
Overall survival
Overall survival at 2 years
Time frame: 2 years
Immunological recovery
Immunological recovery of CD3+ and CD4+ cells in peripheral blood
Time frame: 2 years
Incidence of grade II-IV and III-IV acute GVHD
The incidence of acute GvHD
Time frame: +180 days post transplantation
Incidence of chronic GVHD
The incidence of cGVHD
Time frame: 2 years
Incidence of grade ≥ 3 toxicity Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease
The rates of grade ≥ 3 Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease
Time frame: + 100 days post transplantation
Incidence of grade ≥ 3 toxicity Engraftment Syndrome (ES)
The incidence of engraftment syndome
Time frame: 2 years
Incidence of grade ≥ 3 toxicity Transplant-associated thrombotic microangiopathy (TA-TMA)
The incidence of TA-TMA
Time frame: 2 years
Incidence of grade ≥ 3 toxicity Hemorrhagic Cystitis (HC)
The incidence of HC
Time frame: 2 years
Incidence of grade ≥ 3 infections
The incidence of grade ≥ 3 infections of bacterial, viral and fungal origin
Time frame: 2 years
Health-Related Quality of Life, HRQoL.
HRQoL will be measured at baseline and at certain intervals using the quality of life instrument EQ-5D-Y, (Youth)™which include 2 measurements, the descriptive scale ( i.g. the score 1 is no problems and 3 is a lot of problems) and the VAS scale( 1 is the worst health and 100 is the best health that day).
Time frame: 2 years
Transplant-associated hormonal and gonadal late effects
the date of spontaneous puberty, date of spontaneous menarche for female patients and mean testicular volume for male patients, use of hormonal replacement therapy and use of fertility preservation
Time frame: 2 years
Nutritional status
BMI in kg/m\^2 at baseline and post transplantation
Time frame: 2 years
Started Jun 2022 (actual). Primary completion is estimated for Dec 2029, 90 months after the start.
Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 90 months is close to that.
Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.